Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Meulendijks Didier; de Groot Jan Willem B; Los Maartje; Boers James E; Beerepoot Laurens V; Polee Marco B; Beeker Aart; Portielje Johanna E A; Goey Swan H; de Jong Robert S; Vanhoutvin Steven A L W; Kuiper Maria; Sikorska Karolina; Pluim Dick; Beijnen Jos H; Schellens Jan H M; Grootscholten Cecile; Tesselaar Margot E T; Cats Annemieke

doi:10.1002/cncr.29864

赞分享引用

科研之友

微信

新浪微博

Facebook

分享链接

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

作者：Meulendijks Didier; de Groot Jan Willem B; Los Maartje; Boers James E; Beerepoot Laurens V; Polee Marco B; Beeker Aart; Portielje Johanna E A; Goey Swan H; de Jong Robert S; Vanhoutvin Steven A L W; Kuiper Maria; Sikorska Karolina; Pluim Dick; Beijnen Jos H; Schellens Jan H M; Grootscholten Cecile; Tesselaar Margot E T; Cats Annemieke

来源：Cancer, 2016, 122(9): 1434-1443.

DOI：10.1002/cncr.29864

全文

访问全文

分享分享被引浏览

更新时间：2018-06-21 20:12

Similar
Related
Reference

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

全文

产品服务

站内浏览

服务支持

联系方式

科研之友